Diabetes Roundup: FDA Clears Omnipod 5, Tirzepatide Demonstrates Trial Success, and More

Omnipod 5 FDA Cleared for Use in Adults With Type 2 Diabetes

Wegovy pens with pink tape measure and stethoscope / K KStock - stock.adobe.com

Following FDA clearance, the Omnipod 5 Automated Insulin Delivery System is now indicated for use in adults with type 2 diabetes and is the first and only automated insulin delivery system that is FDA cleared for use in the management of both type 1 and type 2 diabetes (T2D). The Omnipod 5 first received FDA clearance in 2022: In January 2022, the device was cleared for use in individuals aged 6 years and older with type 1 diabetes.

Tirzepatide Demonstrates 94% Diabetes Reduction, 22% Weight Loss in SURMOUNT-1 Study

Eli Lilly and Company has announced positive topline results from its SURMOUNT-1 study evaluating the efficacy and safety of tirzepatide (Zepbound and Mounjaro) for weight management and delay in progression to T2D in adults with pre-diabetes and obesity or overweight. Most notably, tirzepatide reduced the risk of developing T2D by 94% and contributed to an average weight loss of more than 20% among participants taking the medication.

Q&A: Discussing the Dangers of Buying GLP-1s From Online Pharmacies

The rise in popularity of glucagon-like peptide-1 receptor agonists (GLP-1s) since 2022 has resulted in shortages of the drugs and a proliferation of dangerous products being sold through illegal online pharmacies. In a recent study published in JAMA Network Open, investigators from the University of California San Diego set out to determine the risk of sourcing semaglutide from online platforms. In an interview with Drug Topics, Timothy Mackey, MAS, PhD, professor of global health at the University of California, San Diego, member of the Alliance for Safe Online Pharmacies’ Academic Advisory Panel, and author on the study, discussed the dangers associated with sourcing GLP-1s from online pharmacies, what can be done to increase awareness about illegal online pharmacies, and the key role pharmacists play in warning patients about the dangers of sourcing GLP-1s from online platforms.

A Diabetes Intervention in Community Pharmacy Drives Value-Based Health Care

More than 50% of Americans are living with at least 1 chronic health condition. Spending around these conditions continues to grow, including upwards of $100 billion per year on excess hospitalization and $528 billion on the misuse, underuse, and overuse of medications per year. The solution, proposed Jon Easter, lies with pharmacists. In a presentation at the 2024 NACDS Total Store Expo, Easter—a professor of practice, the vice chair of practice advancement, PACE division, and associate faculty director at the University of North Carolina Center for the Business of Health—highlighted the crucial role of community pharmacists in a research project-turned-real–world program that has both improved patient outcomes and allowed pharmacists to be paid for their clinical work.

Pharmacy Forecast: GLP-1 Profitability Expected to Remain a Challenge

Scott Biggs, director of supplier services at IQVIA, and Doug Long, vice president of industry relations at IQVIA, sat down with Drug Topics at the 2024 National Association of Chain Drug Stores Total Store Expo to discuss some of this year’s most significant pharmacy trends. Biggs and Long will review these trends in-depth during their session on Monday, August 19, titled “2024 Pharmacy Trends, Issues, and Forecasts.”

Slideshow: Diabetes and Mental Health, Diet and Exercise for Prevention of T2D

Globally, it is estimated that over 1.3 billion people will have diabetes by the year 2050, which is why it is critical to develop strategies that can successfully control risk factors. Recent research on diabetes has examined its bidirectional relationship with mental health, the significant increase in prevalence over the last decade, and how both diet and exercise can help prevent T2D.

Q&A: Social Drivers, Access to Care Limit Reach of Pharmacy-Based Diabetes Programs

Jasmine Perry, PharmD, CPHQ, senior clinical pharmacist, professional engagement and quality at Blue Cross and Blue Shield of North Carolina, sat down with Drug Topics at the 2024 NACDS Total Store Expo to discuss the importance of addressing care disparities and breaking care barriers in underserved communities.

Don’t get left behind: Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips delivered straight to your inbox.